The Technical Analyst
Janux Therapeutics, Inc. [JANX]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Janux Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.35% $62.41
/ 7 mai 2024 @ 12:54
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 236.00 mill |
| EPS: | -1.270 |
| P/E: | -49.14 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 51.85 mill |
| Avg Daily Volume: | 1.063 mill |
| RATING 2024-05-07 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -49.14 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -49.14 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.950 (-101.52%) $-63.36 |
| Date: 2024-05-07 |
| Expected Trading Range (DAY) |
|---|
|
$ 58.39 - 66.65 ( +/- 6.61%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-04 | Ra Capital Management, L.p. | Buy | 1 397 849 | Pre-Funded Warrants (Right to Buy) |
| 2024-02-29 | Avalon Ventures Xi, L.p. | Sell | 447 949 | Common Stock |
| 2024-02-29 | Avalon Ventures Xi, L.p. | Sell | 438 722 | Common Stock |
| 2024-02-29 | Avalon Ventures Xi, L.p. | Sell | 84 985 | Common Stock |
| 2024-02-29 | Avalon Ventures Xi, L.p. | Buy | 31 456 | Common Stock |
| INSIDER POWER |
|---|
| 55.78 |
| Last 96 transactions |
| Buy: 16 444 752 | Sell: 7 280 818 |
Forecast:
14:34 - $62.80
Live Trading Signals (every 1 min)
Forecast
1: 13:04 - $62.50
Forecast 2: 13:54 - $62.57
Forecast 3: 14:34 - $62.80
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $62.41 (0.35% ) |
| Volume | 0.232 mill |
| Avg. Vol. | 1.063 mill |
| % of Avg. Vol | 21.83 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For JANX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $9.05 | N/A | Active |
|---|
JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Latest Press Releases
2024-03-08 16:01:00 - Press Release
Janux Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Business Highlights
San diego--(business wire)---- $janx--janux therapeutics reports fourth quarter and full year 2023 financial results and business highlights.
2024-02-29 01:22:00 - Press Release
Janux Therapeutics Announces Pricing Of $296.5 Million Underwritten Public Offering Of Common Stock And Pre-funded Warrants
San diego--(business wire)---- $janx--janux therapeutics announces pricing of $296.5 million underwritten public offering of common stock and pre-funded warrants.
2024-02-27 17:00:00 - Press Release
Janux Therapeutics Announces Proposed Public Offering Of Common Stock
San diego--(business wire)---- $janx--janux therapeutics announces proposed public offering of common stock.
2024-02-26 16:05:00 - Press Release
Janux Announces Encouraging Safety And Efficacy Data In Ongoing Dose Escalation Trials For Psmaxcd3-tractr Janx007 In Mcrpc And Egfrxcd3-tractr Janx008 In Solid Tumors
San diego--(business wire)---- $janx--psmaxcd3-tractr janx007 in mcrpc and egfrxcd3-tractr janx008 in solid tumors.
2024-02-20 08:00:00 - Press Release
Janux Therapeutics To Host Virtual Event Discussing Updated Clinical Data For Psma-tractr Janx007 And Egfr-tractr Janx008
San diego--(business wire)---- $janx--janux therapeutics to host virtual event discussing updated clinical data for psma-tractr janx007 and egfr-tractr janx008.
Latest News
2024-04-17 13:12:56 - InvestorPlace
Take the Money and Run: 3 Overbought Stocks to Sell ASAP
Generally, the idea of selling securities rankles the public's nerve, yet trimming overbought stocks is just as important a discipline as knowing what to buy. It might be even more important than the latter concept.
2024-04-16 13:19:09 - InvestorPlace
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.
2024-04-15 13:55:12 - Zacks Investment Research
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.
2024-04-12 09:50:18 - Zacks Investment Research
Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2024-04-12 05:40:00 - The Motley Fool
Why Janux Therapeutics Stock Is Crushing It This Week
Janux Therapeutics' stock jumped this week after a report stated the company was exploring a sale. The company hasn't publicly commented on whether it's involved in acquisition discussions.
2024-04-11 10:55:25 - Zacks Investment Research
Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 40.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-04-10 18:39:00 - The Motley Fool
Why Janux Therapeutics Stock Soared as the Market Sagged Today
According to a media report, among other potential moves, the biotech is considering putting itself up for sale. It has apparently received buyout offers from pharmaceutical companies.
2024-04-08 10:35:19 - Zacks Investment Research
After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX)
Janux Therapeutics (JANX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2024-03-28 13:01:15 - Zacks Investment Research
Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know
Janux Therapeutics (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-22 10:55:20 - Zacks Investment Research
Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.